Previous 10 | Next 10 |
Vericel (VCEL): Q3 GAAP EPS of $0.08 beats by $0.10.Revenue of $32.26M (+5.8% Y/Y) beats by $1.28M.Press Release For further details see: Vericel EPS beats by $0.10, beats on revenue
Total Net Revenues of $32.3 Million and Net Income of $3.6 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe bu...
Vericel (NASDAQ:VCEL) is scheduled to announce Q3 earnings results on Thursday, November 5th, before market open.The consensus EPS Estimate is -$0.03 vs. $0.07 in 3Q19 and the consensus Revenue Estimate is $30.98M (+1.6% Y/Y).Over the last 2 years, VCEL has beaten EPS estimates 75% of th...
[[AAON]], [[AAWW]], [[ABC]], [[ACIW]], [[AEIS]], [[AGIO]], [[ALNY]], [[AMRN]], [[AZN]], [[BABA]], [[BCE]], [[BDX]], [[BLL]], [[BMY]], [[CAH]], [[CCOI]], [[CEVA]], [[CGEN]], [[CHH]], [[CI]], [[CNK]], [[CNP]], [[CNQ]], [[COMM]], [[CORE]], [[CPRI]], [[CRON]], [[CWEN]], [[D]], [[DISCA]], [[DNB]],...
CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced presentations at the following upcoming investor conferences. The Credit Suisse 29 th Annua...
CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its third-quarter 2020 financial results and busin...
Vericel Corporation (VCEL) expects Q3 net revenues of ~$32M vs. consensus of $28.57M: including ~$24.2M of MACI, ~$6.7M of Epicel and ~$1.2M of revenue related to the procurement of NexoBrid. The company generated ~$4.6M of operating cash flow in the quarter.As of September 30, 2020, the comp...
Double-Digit Revenue, Implant and Biopsy Growth for MACI in the Quarter and Record Monthly Biopsies in September Approximately $4.6 Million of Operating Cash Flow for the Quarter CAMBRIDGE, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Verice...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week aheadBig banks will lead off the Q3 earnings season next week with investors likely to see more surprises than normal due to t...
Big banks will lead off the Q3 earnings season next week with investors likely to see more surprises than normal due to the uncertainty of forecasting numbers amid a pandemic. Of note, the 12 largest U.S. banks are all forecast to report a profit. Overall, Q3 profit for S&P 500 companies ...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Karen Mahoney as Chief Human Resources Officer following the retirement of Heidi Hassen, w...
CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its second-quarter 2024 financial results on Thursday, August 1, 2024. Vericel’s m...
2024-07-08 00:00:04 ET Ryan Zimmerman from BTIG issued a price target of $56.00 for VCEL on 2024-07-05 10:09:00. The adjusted price target was set to $56.00. At the time of the announcement, VCEL was trading at $46.68. The overall price target consensus is at $48.00 with...